Key Laboratory of Biomedical Information Engineering of Ministry of Education and Department of Biomedical Engineering, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, P. R. China.
Adv Healthc Mater. 2019 Sep;8(18):e1900720. doi: 10.1002/adhm.201900720. Epub 2019 Aug 13.
Sonodynamic therapy (SDT) not only has greater tissue-penetrating depth compared to photo-stimulated therapies, but also can also trigger rapid drug release to achieve synergistic sonochemotherapy. Here, reactive oxygen species (ROS)-responsive IR780/PTL- nanoparticles (NPs) are designed by self-assembly, which contain ROS-cleavable thioketal linkers (TL) to promote paclitaxel (PTX) release during SDT. Under ultrasound (US) stimulation, IR780/PTL-NPs produce high amounts of ROS, which not only induces apoptosis in human glioma (U87) cells but also boosts PTX released by decomposing the ROS-sensitive TL. In the U87 tumor-bearing mouse model, the IR780/PTL-NPs releases the drug at the target sites in a controlled manner upon US irradiation, which significantly inhibits tumor growth and induces apoptosis in the tumor tissues with no obvious toxicity. Taken together, the IR780/PTL-NPs are a novel platform for sonochemotherapy, and can control the spatio-temporal release of chemotherapeutic drugs during SDT.
声动力学疗法(SDT)不仅具有比光刺激疗法更大的组织穿透深度,而且还可以触发快速药物释放以实现协同声化疗。在这里,通过自组装设计了对活性氧(ROS)响应的 IR780/PTL-纳米颗粒(NPs),其包含 ROS 可裂解硫缩酮键(TL),以在 SDT 期间促进紫杉醇(PTX)的释放。在超声(US)刺激下,IR780/PTL-NPs 产生大量的 ROS,不仅诱导人神经胶质瘤(U87)细胞凋亡,而且还通过分解 ROS 敏感的 TL 来增强 PTX 的释放。在 U87 荷瘤小鼠模型中,IR780/PTL-NPs 在 US 照射时以受控方式在靶部位释放药物,其显著抑制肿瘤生长并诱导肿瘤组织中的细胞凋亡,而无明显毒性。综上所述,IR780/PTL-NPs 是一种新型的声化疗平台,可以在 SDT 期间控制化疗药物的时空释放。